Article
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Haematologica - 1 Sept 2009
Ernst Thomas, Gruber Franz X, Pelz-Ackermann Oliver, Maier Jacqueline, Pfirrmann Markus, Müller Martin C, Mikkola Ingvild, Porkka Kimmo, Niederwieser Dietger, Hochhaus Andreas, Lange Thoralf
Abstract excerpt
BACKGROUND: Various techniques have been employed to detect BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia who are resistant to imatinib. This has led to different reported frequencies of mutations and the finding of a heterogeneous pattern of individual mutations. DESI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.